{"name":"Palleon Pharmaceuticals, Inc.","slug":"palleon-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxQd1ZwWmdvcHZaVm0yOHFjRXJweFZsS0dteHJsblVYZHN5RDlZR2drLXJFNTJYTmNlV2oxRzA0bUZsTzFCOHc5VVE5TUVnXzVKcC1iWmo5MjdYWnNkWHlZWnpRbTkwaFFQM1l1aWhmZHI5Uy1TbVc0TjJzMXN3RzEzelVVTEhBUDBucWNCSVdQSlNZSnE3bHN6NGF2RmROd1Nta015RkpPMGV5OUNoSV95bFlna1BraWJ1TU1mSnEyc1ktYXUtQ1VWOGc1RmpFNGI0TmZwLW9aT0ZXSEFfX0FQWF9TUTFTc1A0ZHVNSEF6ek9GaG9KVDJSYUtpTU9IWWd3TW9iQVhzN0VKY25vcTZ3amxHQlpWUnNG?oc=5","date":"2026-04-02","type":"pipeline","source":"businesswire.com","summary":"Palleon Pharmaceuticals to Present on Development of HLX316/E-688 at the American Association for Cancer Research (AACR) Annual Meeting - businesswire.com","headline":"Palleon Pharmaceuticals to Present on Development of HLX316/E-688 at the American Association for Cancer Research (AACR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxQczFaMW1rekJaNmo3bVNnMEJQUmJkSWxPa0tQYmt0T2I3TW5CY1F3VmQ0eWpKcjZDOWVpMnNFQjFkd01ZSkQwRTI4TDRjTF9KMS1VRFNoODBObDE3elJaVTVZN1lvRmMtVl9COU1LX3dZRFlCSkdfcDYxVzNza1dWSU1ZbUoyUlRyZUt6TVZLVTRHYjhhYnozNG91TzhpTUxoVVhUNjlER0huVGFSV3ctb2gtMWE1NU4wSEhBWkJLbkk1amtmbFhVS09UcVF6QXNQR1dFQmczRDhZZENrUVJRVlVPVDNLaDVqZkJ3R2Vvbi1EYjk2R1dyVU1VQkctaTBKM0EycmZPNXVRQnJ3OWpzVFRrUW0wVWxFdWdqLUhhUUtyV0lsSUdHVmh4MS1XMUJTLS02SzJUWl8xdmYwSDE4?oc=5","date":"2026-04-01","type":"regulatory","source":"GlobeNewswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline - GlobeNewswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-22","type":"pipeline","source":"businesswire.com","summary":"Palleon Pharmaceuticals to Present on Development of HLX79/E-602 in Autoimmune Disease at the American College of Rheumatology Convergence Annual Meeting and the American Society of Nephrology Kidney ","headline":"Palleon Pharmaceuticals to Present on Development of HLX79/E-602 in Autoimmune Disease at the American College of Rheuma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQQlRLM3Bkc0tSNlR6UndWMERMS1o4ak9FWU44UmZMZEZWblpFOTkyRExGQm1ybTRZcGVtaFUzdEhPWUdJUllabVJTOVo1aE1NMk01QlYybU1hRGZpcHVSTmVFdEFueTFEYjlvSzJTVDRaWGktZkJtLWNWZkFXMmdkMUJWUFk4T21KZk4yZXRaUHBTY2wxSWE5ZQ?oc=5","date":"2025-08-07","type":"trial","source":"Yahoo Finance","summary":"Palleon Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of E-602 (HLX79), a Potential First-In-Class Treatment for Active Glomerulonephritis - Yahoo Finance","headline":"Palleon Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of E-602 (HLX79), a Potential First-In-C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxOVXUzbW9WMlF4WGZ5d3A5SUFzaGVJbmxEUVhkU1FTZzNzTlZ4NlVfbDZZU2l2aEt5VmttSjVtdHhvT01sTDAwU0RjUFdlb0J4VjhMQl82Vkg5Qm9rTVRCVDRMLWJRU1JGS3A2SFhZX0hDTjd4eDNrZ01YRF83V1Y5MUVjSXlZOGRxYXhzZ044UnZZMmk0bFpfZ3k2dDhrbU5WNUxVOUVzMnZaOFhoTURoVDB2Z3FMdWVHdVFObFBkczZWcjRzMTQxdW5zVU9uVmFNaTY1d296MzBPdlhHMUxZWGo1YVJNc0FYdEZiUDNMVnRPb1JIcm45bWFJTTlJQnRxSlNOTktaSXYxNEhBUnR6VmMzN0tXcVpadHpfOFBSU0FIZ29TWDhsb1JyMnJURUR4N1JXOHBibEI4dw?oc=5","date":"2025-04-02","type":"trial","source":"businesswire.com","summary":"Palleon Pharmaceuticals Announces NMPA IND Clearance to Proceed with Phase 2 Clinical Trial of E-602 (HLX79), a First-In-Class Treatment for Autoimmune Diseases - businesswire.com","headline":"Palleon Pharmaceuticals Announces NMPA IND Clearance to Proceed with Phase 2 Clinical Trial of E-602 (HLX79), a First-In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_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?oc=5","date":"2024-11-08","type":"trial","source":"businesswire.com","summary":"Palleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in Patients with Solid Tumors at the Society for Immunotherapy of Cancer (SITC) Ann","headline":"Palleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5KYWltUm5DS0RXdklEaGJOdkhEd0kzcU5DNTNsdVhXMkQ2Q0VSaW55OGY5OWxSSHdoTlVsUnVicHNzWE9UM1lJRXhhY09xU3RhMmFQeTZRM2tuZE5jUkM4V2FDQjlQUWMyN1VNalFjbjVZOG45SHdGVTd6a3A?oc=5","date":"2023-08-28","type":"pipeline","source":"Fierce Biotech","summary":"Introducing Fierce Biotech's 2023 Fierce 15 - Fierce Biotech","headline":"Introducing Fierce Biotech's 2023 Fierce 15","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNSHYwWjMtMlNwUkZjVExYOEZQQVMyZEJBcGdoRkd6LU9aTVVjbWMyZlQ3M2dzSGtjT2ZJbzlkVzFWQjN2eXFkc3VlVjZoS3pBbmd3Q1ctVngxQk1EWDVOckhyV3BDa2tsX25CaEdkWnkyNXhVbVRDUzEtTmUtRV9LcFotUnN5QUFlWmpuMHR1WDZ1Vk5vNUJ0RklSNG14Wm4yZXdMclFyeFdRQmRoZTdXLWZVcFJrMjlTb3pyeVJCd0RCUS0yRGhoYi1sTENZaEd1QXI5Wg?oc=5","date":"2023-08-28","type":"pipeline","source":"businesswire.com","summary":"Palleon Pharmaceuticals Recognized as a Fierce Biotech “Fierce 15” Company for 2023 - businesswire.com","headline":"Palleon Pharmaceuticals Recognized as a Fierce Biotech “Fierce 15” Company for 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9rVFBFWE5FLU9sNHBXaHdwZ3dzT2h3VDAyODF1azFxUXQwOXp3WmZQQnNvck9wcnJiQWNpZjRHUmVZWHh2dGFFNVZZcDFVY09sN0p5bXpOVjQxSjVqZkItNA?oc=5","date":"2022-11-04","type":"patent","source":"复宏汉霖","summary":"Henlius Wins Generics Bulletin ‘Business Development of the Year’ Award-Media - 复宏汉霖","headline":"Henlius Wins Generics Bulletin ‘Business Development of the Year’ Award-Media - 复宏汉霖","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}